Evidence map›Paper›PMID 40484917›Full record

ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2025

Frequency of anti-GQ1b IgG antibody in Miller Fisher syndrome: a Chinese single center study.

Pengfei Shao, Wenhui Wu, Xin Zhang, Haifeng Chen, Yun Xu, Qing Ye

Abstract read
PubMed Publisher
In one paragraph

Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Pengfei ShaoDepartment of Neurology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, 210008, China.
Wenhui WuDepartment of Geriatrics, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, 210008, China. wuwenhuixi@126.com.
Xin ZhangDepartment of Neurology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, 210008, China.
Haifeng ChenDepartment of Neurology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, 210008, China.
Yun XuDepartment of Neurology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, 210008, China. xuyun20042001@aliyun.com.
Qing YeDepartment of Neurology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, 210008, China. yeqingyouxiang@126.com.

Funding

Clinical Trials from the Affiliated Drum Tower Hospital 2022-LCYJ-PY-11Jiangsu Commission of Health M2022107 and BJ20003National Natural Science Foundation of China 82101539 and 82101539the Jiangsu Province Stroke Association JSSA20230010Y and JSSA2024ZD01
6 · The paper itself

Abstract

backgroundThe anti-GQ1b IgG antibody has been traditionally regarded as a sensitive marker for Miller Fisher syndrome (MFS). Nevertheless, its prevalence might vary across regions and could be affected by the coronavirus disease 2019 (COVID-19) pandemic. This retrospective study was designed to evaluate the positivity rate of the anti-GQ1b IgG antibody among MFS patients admitted to a single Chinese center and to examine the influence of the COVID-19 pandemic thereon.

methodsWe retrospectively analyzed the medical records of patients diagnosed with MFS and admitted to our hospital from January 2018 to March 2024. Anti-ganglioside antibodies were tested in acute-phase serum samples using enzyme-linked immunosorbent assay (ELISA) or immune-dot assays.

resultsOf the 72 patients admitted for MFS, 51 were tested for ganglioside antibodies. Only 9 (17.65%) of the tested patients were found to have the anti-GQ1b IgG antibody. The positivity rate of the antibody was comparable between patients with the complete form of MFS and those with the incomplete form (17.39% vs. 17.86%, P = 0.965). Additionally, the positivity rate was significantly lower during and after the COVID-19 pandemic compared to before the pandemic (8.33% vs. 40.00%, P = 0.007).

conclusionsThe anti-GQ1b IgG antibody is infrequently detected in MFS patients admitted to our center, especially during and after the COVID-19 pandemic. Future prospective multicenter investigations are expected to contribute significantly to the further clarification of the prevalence of anti-GQ1b IgG antibody in MFS patients across various regions of China.

Indexed as

AutoantibodiesCOVID-19GangliosidesImmunoglobulin GMiller Fisher SyndromeAdolescentAdultAgedChinaEast Asian PeopleFemaleHumansMaleMiddle AgedRetrospective StudiesYoung AdultAutoantibodiesGangliosidesGQ1b gangliosideImmunoglobulin Ganti-GQ1b IgG antibodyChinaCoronavirus disease 2019Miller Fisher syndrome

Identifiers

PMID40484917

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.